Open AccessExtended Use of Histrelin Implant in Pediatric Patients
Author(s) -
Elyse Pine-Twaddell,
Ron S. Newfield,
Maja Marinković
Publication year - 2023
Publication title -
transgender health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.242
H-Index - 20
eISSN - 2688-4887
pISSN - 2380-193X
DOI - 10.1089/trgh.2021.0130
Subject(s) - medicine , central precocious puberty , adverse effect , implant , hormone , precocious puberty , surgery
Histrelin implant (HI) is a gonadotropin-releasing hormone agonist (GnRHa) used in pediatrics to treat central precocious puberty (CPP) and for pubertal suppression in transgender/non-binary (TG/NB) youth with gender dysphoria. HI is designed for annual removal/replacement; however, effectiveness has been reported beyond 1 year. No previous study has assessed prolonged HI use in TG/NB youth. We hypothesize that HI is effective >12 months in TG/NB youth as described in children with CPP.